Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$7.41 ▲ +0.17
(+2.35%)
MKT CAP: $489.2M • VOL: 1.04M
52W L $5 52W H $16
RGNX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $170.4M | $83.3M | $90.2M |
| YoY Revenue Growth % | +104.5% | -7.7% | — |
| Gross Profit | — | $49.8M | — |
| Gross Margin % | — | 59.7% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$161.2M | -$233.3M | -$268.1M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$193.9M | -$227.1M | -$263.5M |
| EBITDA (Normalized) | -$159.3M | -$231.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$124.0M | -$173.1M | -$218.4M |
| Capital Expenditures (CapEx) | $2.4M | $2.4M | — |
| Free Cash Flow (FCF) | -$126.4M | -$175.6M | -$218.4M |
| FCF Margin % | -74.1% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $34.5M | $57.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $102.7M | $259.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR RGNX.